SVG 102
Alternative Names: SVG-102Latest Information Update: 19 Sep 2022
At a glance
- Originator SoVarGen
- Class Antiepileptic drugs; Antisense oligonucleotides
- Mechanism of Action Protein biosynthesis modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Partial epilepsies
Most Recent Events
- 08 Sep 2022 SVG 102 is available for licensing as of 08 Sep 2022. http://www.sovargen.com/rd#section2
- 08 Sep 2022 Preclinical trials in Partial epilepsies in South Korea (Parenteral) prior to September 2022 (SoVarGen pipeline, September 2022)
- 26 Aug 2022 SoVarGen announces intention to submit IND to US FDA and EMA for Partial epilepsies